Featured Publications
Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean changeA systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors
2020
Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlaceboChapter 39 Obsessive–compulsive disorder
Bloch M, Artukoglu B, Lennington J, Szuhay G, Lombroso P. Chapter 39 Obsessive–compulsive disorder. 2020, 663-674. DOI: 10.1016/b978-0-12-813866-3.00039-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsCognitive behavioral therapyTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationBrain stimulantBehavioral therapyMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesFirst-line treatmentSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesNeuroimagingModulating agentsHereditary component
2019
Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis.
Dobson ET, Bloch MH, Strawn JR. Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis. The Journal Of Clinical Psychiatry 2019, 80 PMID: 30753760, DOI: 10.4088/jcp.17r12064.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTolerability of pharmacotherapyTreatment-emergent suicidalityMedication classesTreatment responsePediatric anxiety disordersAnxiety disordersReuptake inhibitorsTolerability of medicationsPlacebo-controlled trialSerotonin reuptake inhibitorsNetwork Meta-AnalysisRisk of biasWeb of ScienceCause discontinuationGeMTC packageSuicidality dataCochrane riskMultiple medicationsBias toolPediatric patientsMedication trialsAgonist treatmentCochrane Database
2018
Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders. Depression And Anxiety 2018, 36: 198-212. PMID: 30479005, DOI: 10.1002/da.22854.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsGreater treatment benefitHigh dosesTreatment responseAnxiety disordersReuptake inhibitorsSymptom improvementTreatment benefitPharmacological agentsRandomized placebo-controlled clinical trialSSRIs/serotonin-norepinephrine reuptake inhibitorsPlacebo-controlled clinical trialIndividual pharmacological agentsCochrane Central RegisterNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsOverall symptom improvementGreater symptom improvementDose-response curveLinear mixed model analysisCentral RegisterMedication classesAdult patientsControlled TrialsChapter 17 Managing a Child With OCD Who Is Treatment Refractory
Bloch M. Chapter 17 Managing a Child With OCD Who Is Treatment Refractory. 2018, 329-356. DOI: 10.1016/b978-0-12-811427-8.00017-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-refractory obsessive-compulsive disorderCognitive behavioral therapyFirst-line treatmentOCD symptomsPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEffective first-line treatmentSelective serotonin reuptake inhibitorsIntensive treatment programSerotonin reuptake inhibitorsGlutamate-modulating agentsMajority of childrenTreatment programAntipsychotic augmentationReuptake inhibitorsTreatment refractoryPharmacological treatmentAvailable treatmentsChildrenSubstantial proportionPharmacotherapyTreatmentTherapySymptoms
2017
Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants
Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants. Depression And Anxiety 2017, 34: 1134-1146. PMID: 28881483, DOI: 10.1002/da.22680.Peer-Reviewed Original ResearchConceptsSSRI/SNRI medicationsSerotonin-norepinephrine reuptake inhibitorsSecond-generation antidepressantsAntidepressant medicationSNRI medicationsMost antidepressant medicationsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisTreatment of adultsReceptor affinity profileMedication classesReuptake inhibitorsMedication typeObsessive-compulsive disorderAntidepressant agentsRisk ratioSubgroup analysisDepressive disorderDopamine transporter affinityHyperhidrosisMedicationsPubMed searchSide effectsDopamine transporterObsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA 2017, 317: 1358-1367. PMID: 28384832, DOI: 10.1001/jama.2017.2200.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment of OCDReuptake inhibitorsBehavioral therapySystematic reviewFirst-line pharmacologic interventionPreferred initial treatment strategyTreatment-resistant obsessive-compulsive disorderInitial treatment strategyPrimary care settingTreatment-resistant casesDiagnosis of OCDFirst-line interventionEfficacy of neurolepticsDeep brain stimulationComputer-based cognitive behavioral therapyCase seriesPharmacologic interventionsAdjunctive useTreatment optionsTreatment advancesNeuromodulatory approaches
2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG, Jakubovski E, Bloch MH. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. The Journal Of Clinical Psychiatry 2016, 77: e1262-e1269. PMID: 27631142, DOI: 10.4088/jcp.15m10075.Peer-Reviewed Original ResearchConceptsMajor depressive disorderCitalopram treatmentSuicidal ideationClinical predictorsClinical variablesSelective serotonin reuptake inhibitorsNonpsychotic major depressive disorderFirst-line treatmentBaseline clinical variablesSerotonin reuptake inhibitorsWeeks of treatmentSequenced Treatment AlternativesSide effect dataGreater likelihoodTime coursePhase 1Cardiac comorbiditiesNeurologic comorbiditiesBaseline characteristicsSedative medicationsReuptake inhibitorsTrial phase 1Clinical correlatesQuick InventoryDepressive disorderSystematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder
Varigonda AL, Jakubovski E, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2016, 55: 851-859.e2. PMID: 27663940, PMCID: PMC6944467, DOI: 10.1016/j.jaac.2016.07.768.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric obsessive-compulsive disorderSerotonin reuptake inhibitorsObsessive-compulsive disorderYale-Brown ObsessiveReuptake inhibitorsTime courseEarly treatment responseTreatment effectsChildren's Yale-Brown ObsessiveSSRI agentsPlacebo groupSSRI treatmentAdult patientsTreatment responsePooled estimatesPharmacological responseHigh dosesMeta-AnalysisSystematic reviewClomipramineSymptom dataMagnitude of responseMean differenceCompulsive ScaleEarly onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorderSystematic Review of Pharmacological and Behavioral Treatments for Skin Picking Disorder
Schumer MC, Bartley CA, Bloch MH. Systematic Review of Pharmacological and Behavioral Treatments for Skin Picking Disorder. Journal Of Clinical Psychopharmacology 2016, 36: 147-152. PMID: 26872117, PMCID: PMC4930073, DOI: 10.1097/jcp.0000000000000462.Peer-Reviewed Original ResearchConceptsInactive control conditionsUncontrolled trialsBehavioral treatmentSystematic reviewLarger placebo-controlled RCTsSelective serotonin reuptake inhibitorsShort-term clinical trialsBehavioral interventionsPlacebo-controlled RCTsSerotonin reuptake inhibitorsSkin picking disorderEfficacy of treatmentNovel pharmacological agentsShort-term trialsReuptake inhibitorsTreatment armsControl conditionClinical trialsDemonstrated efficacyPsychiatric disordersPharmacological agentsSignificant improvementElectronic databasesRCTsMeta-Analysis
2015
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder
Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. American Journal Of Psychiatry 2015, 173: 174-183. PMID: 26552940, PMCID: PMC4975858, DOI: 10.1176/appi.ajp.2015.15030331.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsMajor depressive disorderSerotonin reuptake inhibitorsDepressive disorderHigh dosesTreatment responseReuptake inhibitorsBenefit of SSRIsEfficacy of SSRIsTolerability of SSRIsEffects of SSRIsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisTherapeutic dose rangeDose-response relationshipSSRI doseTolerability analysisMedication dosesSignificant positive associationSubgroup analysisMultiple time pointsDose categoriesMixed regression modelsCause dropoutsSystematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 557-564. PMID: 26088660, DOI: 10.1016/j.jaac.2015.05.004.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric major depressive disorderMajor depressive disorderSerotonin reuptake inhibitorsSSRI agentsReuptake inhibitorsPediatric depressionDepressive disorderAdult major depressive disorderFirst-line pharmacological treatmentEarly treatment responseIndividual patient dataStandardized mean differenceMDD trialsSSRI doseSSRI pharmacotherapyPlacebo groupAdult patientsSSRI responsePharmacological treatmentPharmacological trialsTreatment responsePooled estimatesPharmacological responseHigh dosesAssessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatmentChapter 106 Obsessive–Compulsive Disorder
Bloch M, Lennington J, Szuhay G, Lombroso P. Chapter 106 Obsessive–Compulsive Disorder. 2015, 1301-1310. DOI: 10.1016/b978-0-12-410529-4.00106-6.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationThalamo-cortical circuitsMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesModulating agentsNeuroimagingHereditary componentCompulsionDeep brainObsession
2014
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C, Bloch MH. Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2014, 37: 375-391. PMID: 25150568, PMCID: PMC4143776, DOI: 10.1016/j.psc.2014.05.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPharmacological treatmentLow-dose neuroleptic medicationsSelective serotonin reuptake inhibitorsProfound clinical challengeSecond-line treatmentSerotonin reuptake inhibitorsSignificant symptomatic reliefTricyclic clomipramineAppropriate pharmacotherapyNeuroleptic medicationReuptake inhibitorsSubstantial morbiditySymptomatic reliefAvailable treatmentsClinical challengeHigh dosesOCD refractoryTreatmentDisordersMedicationsMorbidityPharmacotherapyPatientsClomipramine
2013
LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors
2011
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alpha